Stocks
Regeneron Pharmaceuticals, Inc.REGN
NASDAQHealthcareBiotechnology$745.77-0.11%
A biotechnology developer focused on monoclonal antibody therapies and other biologic medicines used to treat conditions including eye disease, cancer, and inflammatory disorders. Its commercial portfolio includes blockbuster drugs such as Eylea for retinal diseases and Dupixent, partnered with Sano...
Market Cap: $77.5B52W Range: $476.49 – $821.11
Congressional Interest in Regeneron Pharmaceuticals, Inc. (REGN)
12 members of Congress have disclosed 50 trades in Regeneron Pharmaceuticals, Inc. (REGN), a Healthcare company. The buy/sell breakdown shows 17 purchases versus 33 sales, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
50
Unique Politicians
12
Buys
17
Sells
33
Who in Congress Is Trading REGN?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2026-02-12 | Julia Letlow | buy | $1K – $15K |
| 2026-01-29 | Rohit Khanna | sell | $1K – $15K |